Dominguez-Mozo, Maria Inmaculada
Perez-Perez, Silvia
Villar, Luisa María
Oliver-Martos, Begoña
Villarrubia, Noelia
Matesanz, Fuencisla
Costa-Frossard, Lucienne
Pinto-Medel, María Jesús
García-Sánchez, María Isabel
Ortega-Madueño, Isabel
Lopez-Lozano, Lorena
Garcia-Martinez, Angel
Izquierdo, Guillermo
Fernández, Óscar
Álvarez-Cermeño, Jose Carlos
Arroyo, Rafael
Alvarez-Lafuente, Roberto
Funding for this research was provided by:
Formación de Profesorado Universitario” -Ministerio de Educación, Cultura y Deporte (FPU16/00969)
Spanish Biobanks Network (PT13/0010/0041)
REEM: Red Española de Esclerosis Múltiple (RD16/0015/0016, RD16/0015/0013, RD16/0015/0016, RD16/0015/0013)
Instituto de Salud Carlos III (ISCIII)-Fondo Europeo de Desarrollo Regional (PI15/00821)
Fundación Ramón Areces (CIVP18A3860)
Fundación LAIR
Article History
Received: 12 February 2020
Accepted: 17 June 2020
First Online: 28 August 2020
Competing interests
: MIDM, SPP, BOM, NV, FM, MJPM, MIGS, IOM, LLL, MAGM, LMV, JCAC have no conflict of interest. LCF reports personal fees and non-financial support from Biogen, personal fees and non-financial support from Bayer, personal fees and non-financial support from Merck, personal fees and non-financial support from Novartis, personal fees and non-financial support from Roche, personal fees and non-financial support from Teva, outside the submitted work. GI received honoraria as consultant to advisory boards, and as chairman or lecturer in meetings, and has participated in clinical trials and other research projects promoted by Almirall, Actelion, Allergan Bayer-Schering, Biogen Idec, Novartis, Merck-Serono, Roche, and Teva. OF received honoraria as consultant to advisory boards, and as chairman or lecturer in meetings, and has participated in clinical trials and other research projects promoted by Almirall, Actelion, Allergan Bayer-Schering, Biogen Idec, Novartis, Merck-Serono, Roche, and Teva. RA grants, reports personal fees and non-financial support from Novartis, personal fees and non-financial support from Roche, personal fees and non-financial support from Genzyme, personal fees and non-financial support from Teva, personal fees and non-financial support from Biogen, personal fees and non-financial support from Merck, outside the submitted work. RAL reports grants, personal fees and non-financial support from Novartis, non-financial support from Roche, personal fees and non-financial support from Genzyme, non-financial support from Teva, personal fees and non-financial support from Biogen, outside the submitted work.